NASH Observatory

⏿ The PanNASH Initiative is an interactive web-based platform presenting global NASH statistics to inform NASH control and research.

NASH Observatory Commented Articles

The diabetologist, NAFLD and T2D

The prevalence of NASH among patients with type 2 diabetes (T2D) is high, putting them at a significantly higher risk for developing end-stage liver disease, HCC, and CVD. There is a vicious circle, each condition worsening the other. Patients with NAFLD have an increased risk of developing type 2 diabetes, while the latter...

ByDr. G. Bozet, MD
OnFebruary 11, 2021

NASH Observatory Commented Articles Epidemiology Articles

COVID-19: incidence in patients with metabolic syndrome and NASH

Although a relationship between metabolic syndrome and COVID-19 severity might exist, it is currently unclear whether NASH is associated with a higher risk of SARS-CoV-2 infection. The primary objective of this study by S. Ghoneim et al. (Department of Internal Medicine, MetroHealth Medical Center, Cleveland, Ohio, USA) was to identify...

ByDr. G. Bozet, MD
OnFebruary 8, 2021

NASH Observatory Commented Articles

COVID-19 in NAFLD

Recent papers confirm that the relation between metabolic syndrome and mortality rate of COVID-19 is more and more evident. These diseases are often treated with ACE inhibitors, which might upregulate ACE2 expression. ACE2 is normally expressed in low amounts in cholangiocytes and hepatocytes, but was shown to increase...

ByDr. G. Bozet, MD
OnFebruary 7, 2021

NASH Observatory Commented Articles

Weight gain and risk of NAFLD: the Nurses’ Health Study II cohort

besity has been identified as a major risk factor for the development of Non-alcoholic fatty liver disease (NAFLD). However, the influence of dynamic changes in adiposity over the life course on NAFLD risk remains poorly understood. MN Kim et al. collected data from 110,054 women enrolled in the Nurses’ Health Study II cohort. They documented...

ByDr. G. Bozet, MD
OnFebruary 1, 2021

NASH Observatory Commented Articles

Economic and Clinical Burden of NASH in T2D patients in the U.S.

Nonalcoholic steatohepatitis (NASH), the aggressive form of nonalcoholic fatty liver disease (NAFLD) is strongly associated with type 2 diabetes mellitus. Patients with both T2DM and NASH have increased risk for adverse clinical outcomes, leading to higher risk for mortality and morbidity. Using a Markov model with 1-year cycles...

ByDr. G. Bozet, MD
OnFebruary 1, 2021

NASH Observatory

Management of patients with Type 2 Diabetes (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)

Discover the very special relationship between Non-alcoholic fatty liver disease (NAFLD) and Type 2 Diabetes (T2DM) with Prof Kenneth Cusi, USA. Each of these conditions seems to worsen the other.

ByProf. Kenneth Cusi
OnFebruary 1, 2021

NASH Observatory Commented Articles

The epidemic of the 21st century in search of the most appropriate name

Despite their high prevalence, nonalcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) remain largely underdiagnosed and undertreated. Some question the name of the disease. To address this issue, some academic societies contribute...

ByDr. G. Bozet, MD
OnJanuary 19, 2021

NASH Observatory Commented Articles

MAFLD and risk of CKD

Nonalcoholic fatty liver disease (NAFLD) is part of a systemic disease that affects many other parts of the body. The association between MAFLD (metabolic (dysfunction)-associated fatty liver disease) and extra-hepatic diseases is not known. The aim of the cross-sectional study by DQ Sun et al. was to compare the prevalence of chronic...

ByDr. G. Bozet, MD
OnJanuary 19, 2021

NASH Observatory Commented Articles

NAFLD cirrhosis: a predictive model of liver decompensation

Non-alcoholic fatty liver disease (NAFLD) has become the most frequently encountered chronic liver disease and is an increasingly important cause of liver cirrhosis as well as other adverse events. The authors of this article retrospectively developed and validated a model to predict hepatic decompensation in NAFLD patients with cirrhosis and compared...

ByDr. G. Bozet, MD
OnJanuary 14, 2021

Management Articles Commented Articles NASH Observatory

Current management of NASH

NASH is the most common cause of liver disease in Western populations, and its prevalence is increasing rapidly. It is a multifactorial and multisystem disease that can affect multiple organs such as the kidneys, heart and blood vessels, and is closely associated with the components of the metabolic syndrome...

ByDr. G. Bozet, MD
OnJanuary 14, 2021

NASH Observatory Commented Articles Ppar Articles

PPARs and immune responses

Peroxisome proliferator-activated receptors (PPARs) are fatty acid-activated transcription factors of nuclear hormone receptor superfamily that regulate energy metabolism. Currently, three PPAR subtypes have been identified: PPARα, PPARγ, and PPARβ/δ. PPARα and PPARδ are highly expressed in oxidative tissues and regulate genes involved in substrate delivery...

ByDr. G. Bozet, MD
OnJanuary 14, 2021

NASH Observatory Commented Articles

NAFLD/NASH and pleiotropic effects of statins

Statins and NAFLD/NASH, a lipid-related pathology present a complex relationship. As a matter of fact, some statins are known to be hepatotoxic, even though it seems clinically significant hepatic injury caused by lipid-lowering medications remains rare. A question can be asked: is it possible that statins...

ByDr. G. Bozet, MD
OnJanuary 12, 2021